Compare OSPN & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | CCCC |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.5M | 404.7M |
| IPO Year | 2000 | 2020 |
| Metric | OSPN | CCCC |
|---|---|---|
| Price | $15.52 | $3.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.67 | $12.20 |
| AVG Volume (30 Days) | 373.6K | ★ 4.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ 28.77 | 16.45 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $243,180,000.00 | $35,947,000.00 |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $51.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $10.07 | $1.69 |
| 52 Week High | $16.41 | $5.17 |
| Indicator | OSPN | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 42.38 |
| Support Level | $14.95 | $2.10 |
| Resistance Level | $16.09 | $3.89 |
| Average True Range (ATR) | 0.53 | 0.37 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 73.87 | 15.03 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.